human
metapneumoviru
hmpv
emerg
import
etiolog
agent
upper
lower
respiratori
tract
infect
especi
young
children
although
rapid
simpl
diagnost
method
hmpv
need
clinic
laboratori
routin
diagnost
test
readili
avail
purpos
studi
evalu
commerci
antihmpv
monoclon
antibodi
direct
antigen
test
shell
vial
cultur
hmpv
pilot
studi
nasopharyng
aspir
children
acut
respiratori
tract
infect
posit
hmpv
revers
transcriptas
polymeras
chain
reaction
rtpcr
test
direct
antigen
test
shell
vial
cultur
detect
hmpv
nasopharyng
aspir
initi
diagnosi
larger
group
prospect
studi
nasopharyng
aspir
children
acut
respiratori
tract
infect
test
hmpv
rtpcr
direct
antigen
test
shell
vial
cultur
direct
antigen
test
shell
vial
cultur
show
posit
specimen
posit
rtpcr
find
indic
direct
antigen
test
shell
vial
cultur
would
reliabl
time
method
diagnosi
hmpv
infect
clinic
laboratori
elsevi
bv
right
reserv
human
metapneumoviru
hmpv
newli
describ
rna
viru
famili
paramyxovirida
subfamili
pneumovirina
along
respiratori
syncyti
viru
rsv
kahn
viru
respiratori
viral
pathogen
caus
upper
lower
respiratori
tract
infect
individu
age
particularli
young
children
chung
et
al
hamelin
boivin
van
den
hoogen
et
al
commun
health
care
set
worldwid
bastien
et
al
falsey
et
al
fouchier
et
al
van
den
hoogen
et
al
preval
hmpv
children
acut
respiratori
tract
infect
estim
vari
chung
et
al
hamelin
boivin
kahn
principi
et
al
van
den
hoogen
et
al
william
et
al
make
second
third
preval
pathogen
children
acut
respiratori
tract
infect
rsv
possibl
rhinoviru
preval
garciagarcia
et
al
koetz
et
al
principi
et
al
sarasini
et
al
william
et
al
hmpv
first
diagnos
revers
transcriptas
polymeras
chain
reaction
rtpcr
van
den
hoogen
et
al
still
refer
method
diagnosi
viru
also
isol
convent
cell
cultur
use
vero
cell
tang
crow
rtpcr
readili
avail
clinic
laboratori
due
clinic
import
hmpv
rapid
simpl
diagnost
method
requir
recent
fitcconjug
monoclon
antibodi
specif
hmpv
becom
commerci
avail
purpos
studi
evalu
perform
antibodi
diagnosi
hmpv
direct
antigen
test
shell
vial
cultur
pilot
studi
nasopharyng
aspir
obtain
children
posit
hmpv
rtpcr
rtpcr
perform
use
seeplex
rv
detect
kit
seegen
biotechnolog
inc
seoul
korea
sung
et
al
pcr
product
posit
specimen
sequenc
consist
hmpv
hmpv
strain
detect
studi
classifi
strain
genogroup
one
strain
genogroup
strain
genogroup
followup
nasopharyng
aspir
obtain
patient
day
respect
patient
day
initi
diagnosi
nasopharyng
aspir
store
c
day
prior
direct
antigen
test
shell
vial
cultur
rtpcr
posit
specimen
centrifug
g
min
cell
pellet
spot
onto
slide
fix
slide
incub
fitcantihmpv
monoclon
antibodi
dfa
metapneumoviru
diagnost
hybrid
inc
athen
oh
usa
min
c
addit
viru
cultur
rmix
cell
diagnost
hybrid
inc
one
shell
vial
cryopreserv
rmix
cell
monolay
thaw
min
medium
remov
new
medium
ad
l
patient
specimen
supernat
inocul
see
front
matter
elsevi
bv
right
reserv
vial
centrifug
g
min
room
temperatur
incub
c
co
incub
coverslip
contain
cell
fix
aceton
stain
dfa
metapneumoviru
stain
slide
examin
use
fluoresc
microscop
patient
medic
record
review
retrospect
demograph
find
clinic
diagnos
nasopharyng
aspir
posit
hmpv
rtpcr
initi
diagnosi
posit
stain
dfa
metapneumoviru
direct
antigen
test
shell
vial
cultur
use
method
hmpvinfect
human
respiratori
cell
nasopharyng
aspir
rmix
cell
show
fine
granular
reticular
fluoresc
cytoplasm
fig
one
nasopharyng
aspir
pneumon
patient
store
day
test
neg
hmpv
direct
antigen
test
shell
vial
cultur
three
followup
nasopharyng
aspir
obtain
patient
day
second
patient
day
initi
diagnosi
posit
direct
antigen
test
shell
vial
cultur
one
followup
nasopharyng
aspir
obtain
specimen
taken
day
initi
diagnosi
pneumonia
neg
method
prior
test
specimen
store
day
respect
median
age
children
hmpv
month
rang
month
year
male
fourteen
patient
less
year
old
less
year
old
ten
patient
diagnos
pneumonia
bronchiol
clinic
sepsi
patient
neg
rsv
influenza
viru
parainfluenza
viru
adenoviru
direct
antigen
test
shell
vial
test
rtpcr
coronaviru
rhinoviru
rtpcr
coinfect
bacteria
observ
larger
group
prospect
studi
nasopharyng
aspir
children
acut
respiratori
tract
infect
test
hmpv
rtpcr
direct
antigen
test
shell
vial
cultur
accord
establish
method
sampl
neg
rsv
influenza
viru
parainfluenza
viru
adenoviru
initi
screen
direct
antigen
test
ultra
dfa
respiratori
viru
screen
id
kit
diagnost
hybrid
inc
direct
antigen
test
shell
vial
cultur
show
posit
specimen
posit
rtpcr
rtpcrneg
sampl
neg
hmpv
direct
antigen
test
shell
vial
cultur
neg
specimen
direct
antigen
test
shell
vial
cultur
nasopharyng
aspir
patient
pneumonia
whose
antimycoplasm
antibodi
titer
particl
agglutin
test
refer
rang
patient
less
year
three
male
three
patient
diagnos
pneumonia
two
patient
bronchiol
studi
rtpcrposit
specimen
initi
diagnosi
posit
hmpv
direct
antigen
test
shell
vial
cultur
previou
report
direct
antigen
test
hmpv
dfa
metapneumoviru
diagnost
hybrid
inc
show
sensit
specif
compar
inhous
rtpcr
sensit
specif
compar
nuclisen
hmpv
biomerieux
durham
nc
usa
manji
et
al
although
number
specimen
small
direct
antigen
test
least
equival
shell
vial
cultur
detect
hmpvposit
specimen
high
posit
rate
direct
antigen
test
shell
vial
cultur
may
due
specimen
nasopharyng
aspir
collect
initi
diagnosi
consid
best
specimen
direct
antigen
test
respiratori
virus
clinic
laboratori
standard
institut
addit
use
dfa
metapneumoviru
mixtur
hmpvspecif
murin
monoclon
antibodi
detect
subtyp
hmpv
may
contribut
high
sensit
direct
fluoresc
antibodi
antibodi
origin
design
percival
et
al
sensit
specif
posit
predict
valu
neg
predict
valu
report
respect
percival
et
al
gerna
et
al
two
specimen
neg
direct
antigen
test
specimen
also
neg
shell
vial
cultur
rtpcr
suffici
sensit
detect
viral
rna
respiratori
specimen
sever
week
live
viru
shed
ceas
tang
crow
specimen
rtpcr
posit
direct
antigen
testand
shell
vial
cultureneg
may
signifi
activ
infect
low
viral
load
recent
acut
infect
shell
vial
cultur
direct
antigen
test
may
therefor
supplement
rtpcr
determin
clinic
signific
hmpv
posit
result
latter
three
followup
specimen
direct
antigen
testposit
specimen
collect
day
initi
diagnosi
neg
sinc
patient
pneumonia
bronchiol
may
excret
hmpv
week
surpris
find
patient
hmpv
neg
day
initi
diagnosi
addit
hmpv
direct
antigen
test
use
dfa
metapneumoviru
current
viral
screen
panel
target
rsv
influenza
viru
parainfluenza
viru
adenoviru
provid
complet
diagnosi
respiratori
viral
infect
young
children
shell
vial
cultur
result
use
rmix
dfa
metapneumoviru
show
complet
agreement
direct
antigen
test
result
specimen
initi
diagnosi
followup
hmpv
replic
poorli
convent
cell
cultur
use
diagnosi
respiratori
virus
includ
mink
lung
madindarbi
canin
kidney
mdck
cell
tang
crow
addit
primari
isol
hmpv
facilit
low
concentr
trypsin
appropri
isol
respiratori
virus
except
influenza
viru
clinic
laboratori
standard
institut
tang
crow
hmpv
first
isol
passag
primari
monkey
kidney
cell
van
den
hoogen
et
al
isol
convent
cultur
use
vero
cell
landri
et
al
isol
howev
requir
long
incub
period
sever
blind
passag
observ
cytopath
effect
posit
sampl
nasopharyng
aspir
posit
hmpv
rtpcr
contrast
shell
vial
cultur
use
rmix
cell
cultur
method
support
growth
hmpv
show
sensit
direct
fluoresc
antibodi
posit
specimen
shell
vial
cultur
use
rmix
would
thu
rapid
reliabl
diagnost
method
hmpv
conclus
direct
shell
vial
cultur
use
dfa
metapneumoviru
would
use
routin
rapid
diagnosi
hmpv
infect
clinic
laboratori
conflict
interest
relat
articl
